Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)

Completed · Phase 4

Conditions studied: Diabetic Macular Edema, Epiretinal Membrane

In brief

This study will examine the use of the dexamethasone implant (Ozurdex) in patients with macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention. After the surgery is performed (pars plana vitrectomy), an Ozurdex implant will be placed in the eye. Patients will be followed for 1 year.

Key facts

Study ID

NCT01613716

Run by

The Cleveland Clinic

People needed

30

Starts

2012-07-01

Expected to finish

2017-02-01

Last updated by the study team

2018-05-16

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are undergoing pars plana vitrectomy for:
• Epiretinal membrane/vitreomacular traction or
• Diabetic macular edema
• Patients with macular edema as measured by OCT (at least 250 um central subfoveal thickness)
• Informed consent requirements: All study subjects must agree to participate in the study and provide written informed consent, which will be written in English.
• Age between 18-85 years old

You may not qualify if…

• Age < 18 years or > 85 years
• History of macular edema due to diseases other than those in the inclusion criteria in the study eye
• History of active inflammatory eye disease (uveitis) (within 3 months)
• History of ocular malignancy and/or ocular/orbital irradiation
• History of recent retinal vein occlusion (within 6 months)
• History of neovascular age-related macular degeneration or choroidal neovascular membrane [
• History of juxtafoveal telangiectasia
• History of Coat's disease
• History central serous choroidoretinopathy
• History of previous infectious retinitis (toxoplasmosis, acute retinal necrosis, tuberculosis, etc)
• Patients with a history of intraocular infection in the study eye (i.e. viral retinitis, endophthalmitis)
• Patients who are cognitively impaired or those who are unable to provide informed written consent
• Patients with a history of glaucoma in the study eye (defined as increased cup to disc ratio with associated nerve damage. Patients with ocular hypertension controlled by topical glaucoma drops (maximum 3) will not be excluded).
• Patient with recent intravitreal injections of steroids or anti-VEGF medications in the study eye (within past 4 weeks).
• Patients with recent periocular steroid injection (within past 4 weeks) in the study eye
• Patients on topical NSAIDS drops (patient will be eligible if they discontinue use of topical NSAIDs at time of study enrollment) in the study eye

Where it is running

• Cole Eye Institute, Cleveland Clinic — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.